Genetic Testing for Autoinflammatory Disease Not all patients with periodic fevers fit neatly into diagnostic categories. Some can be diagnosed as Still’s disease (based on criteria) while others can be classified as AID and some may be unclassifiable. https://t.co/E5qZS1JyAY https://t.co/PYgUbiduPF

• https://bit.ly/3BeF94M

Nintedinib has been studied in 39 children (6–17 yrs) with fibrosing ILD demonstrating pharmacokinetics (wt based dosing) and safety. Adjusted mean changes in FVC % at week 24 were 0.3 with nintedanib and −0.9 with placebo https://t.co/yQ7OREzpTR https://t.co/iylG9BZiz4

• https://bit.ly/3eslLZr

B12 or Placebo effect? Open label study of B12 (1000mcg/d) in 29 fibromyalgia pts showed after 50d, significant reductions in FM Impact Quest. (FIQR; 49.8 to 40.00; p< 0.01), Function, Sxs, anxiety scores all signif improved. https://t.co/MtJWy5xlz9 https://t.co/kzvA1wd3zb

• https://bit.ly/3QiWSMI

FDA has approved SPEVIGO® (spesolimab-sbzo) an IV injection - the first-approved treatment option for generalized pustular psoriasis (GPP) FLARES. Spesolimab is an interleukin-36 receptor antagonist. https://t.co/izmExVCvfQ https://t.co/FELKR70UMv

• https://bit.ly/3wY0JIo

Dr. Jack Cush discusses declining survival rates in the USA, FDA approvals of new COVID subvariant boosters and other odd and possibly true new research reports from the past week on RheumNow. https://t.co/JqzZRu2HYR https://t.co/XefaHown4g https://t.co/XiMyDLhKIe

• https://bit.ly/3TK9AXO
• https://bit.ly/3ANHPoK

Risk of TNFi-related psoriasis in 5088 TNFi Rx children w/ IBD, JIA, or CNO. Compared to non-TNFi exposed, kids on TNFi had an increased PSO risk w/ ADA (IRR 2.70; 1.53-4.75), infliximab (2.34) or etanercept (2.21) & not incr w/ DMARD use https://t.co/Y1Vn9kjk5N https://t.co/5CCxa5kMcU

• https://bit.ly/3q9XXw0

A Rheum & Derm Conversation on Treating PsA and Moderate-to-Severe PsO Sponsored by Lilly USA Listen to Philip Mease and April Armstrong discuss a multidisciplinary approach and importantconsiderations when treating patients with joint and skin concerns. https://t.co/lTfz2kUr51

• https://bit.ly/3CPspmn

NICE Guidelines on Gout Diagnosis and Management NICE (UK) has systematically reviewed current medical evidence and delivered a set of recommendations with consideration of cost effectiveness. https://t.co/a8iyCe3szJ https://t.co/6Jy7dOT4yX

• https://bit.ly/3q6ZpPy

Gout: diagnosis and management—summary of NICE guidance https://t.co/tVHkSMusk6 https://t.co/A7U1DlI7tO

• https://bit.ly/3QaY44N

SURPRISED? Psoriasis pts have a known increased risk of CV disease. But did you know several papers & metanalyses show increased risk of abdominal aortic aneurysm in PSO (HR 1.30), worse w/ dz activity; lost w/ age, female, DM? https://t.co/9ihyubUgCI https://t.co/W1JiXV0yOX https://t.co/Nq6aVBjPuK

• https://bit.ly/3TGmAh3
• https://bit.ly/3cHO2dM

Review of IL-1 inhibitors in recurrent idiopathic pericarditis. While Rilonacept is FDA approved (320 mg x1 then 160 mg sc/wk), anakinra (2 mg/kg/d or 100 mg/d), canakinumab and colchicine are used https://t.co/j00yWpBbq3 https://t.co/7BK2mopssc

• https://bit.ly/3CS1Jl6

USPSTF recommends clinicians prescribe Statins for the primary CVD prevention in adults (40-75 yrs) w/ 1 or more CVD risk factors (ie, dyslipidemia, DM, HTN, smoking) & 10-year CVD risk of 10% or greater. Inflammatory dz is considered a CV risk enhancer https://t.co/1Opblbiz7B https://t.co/xSw2uPUoKK

• https://bit.ly/3wTFeIS

Review of steroids & immunosuppressants on cancer outcomes in checkpoint inhibitor therapy - Steroid use "for irAEs may not have a large deleterious effect on overall survival" - DMARDs for irAE "a major drawback in the delay in the onset of response" https://t.co/8o8JBMpqML https://t.co/bWuLT3zYPm

• https://bit.ly/3KNZ6mq

MIRROR study lead to pegloticase (PEG) label change - adding MTX as Rx to reduced anti-PEG Abs. Based on 14 refractory gout pts given MTX 15mg/wk (w/ folate) and then PEG IV: 3 nonresponders, 1 dropped out, 10 responded/stayed on Rx x 52 wks w/ less ADAbs https://t.co/BZwY7DpmIb https://t.co/gNhhuhmTG5

• https://bit.ly/3RxahBZ